See more : Daechang Co., Ltd. (012800.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Rasna Therapeutics, Inc. (RASP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rasna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Anima Holding SpA (ANIM.MI) Income Statement Analysis – Financial Results
- Dream International Limited (1126.HK) Income Statement Analysis – Financial Results
- Charlotte’s Web Holdings, Inc. (CWBHF) Income Statement Analysis – Financial Results
- Sachem Capital Corp. 7.75% Note (SCCC) Income Statement Analysis – Financial Results
- Sino-Ocean Group Holding Limited (SIOLY) Income Statement Analysis – Financial Results
Rasna Therapeutics, Inc. (RASP)
About Rasna Therapeutics, Inc.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -350.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 314.00 | 1.64K | 3.47K | 4.83K | 3.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -314.00 | -1.64K | -3.47K | -4.83K | -3.46K | 0.00 | 0.00 | -350.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 92.25K | 83.84K | 55.20K | 0.00 | 14.37K | 324.61K | 1.56M | 0.00 | 1.13M | 0.00 | 0.00 |
| General & Administrative | 287.37K | 300.07K | 247.81K | 556.50K | 900.80K | 3.75M | 2.97M | 578.11K | 16.76K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -515.88K | 0.00 | 0.00 | 0.00 |
| SG&A | 287.37K | 300.07K | 247.81K | 556.50K | 900.80K | 3.75M | 2.97M | 62.23K | 16.76K | 40.04K | 5.36K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.94M | 75.23K | 403.29M | 100.80K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.24M | 383.91K | 247.81K | 556.50K | 915.17K | 4.07M | 4.53M | 62.23K | 16.76K | 40.04K | 5.36K |
| Cost & Expenses | 4.23M | 383.91K | 247.81K | 556.50K | 915.17K | 4.07M | 4.53M | 62.23K | 16.76K | 40.04K | 5.36K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 212.97K | 940.99K | 515.91K | 41.44K | 27.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.86M | 314.00 | 314.00 | 1.64K | 3.47K | 4.83K | 3.46K | 578.11K | 1.77M | 0.00 | 0.00 |
| EBITDA | -379.62K | 254.41K | -247.50K | -554.87K | -912.93K | -4.07M | -4.53M | -62.23K | -16.76K | -40.04K | -5.36K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 11,438.57% | 0.00% |
| Operating Income | -4.24M | 141.09K | -247.81K | -5.43M | -915.17K | -4.07M | -4.53M | -62.23K | -16.76K | -40.04K | -5.36K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 11,438.57% | 0.00% |
| Total Other Income/Expenses | -204.12K | -827.68K | -628.18K | 79.15K | -28.79K | -6.30K | 100.80K | 0.00 | 1.77M | 0.00 | 0.00 |
| Income Before Tax | -4.44M | -686.59K | -785.08K | -5.35M | -943.96K | -4.07M | -4.43M | -62.23K | -16.76K | -40.04K | -5.36K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 11,438.57% | 0.00% |
| Income Tax Expense | 0.00 | -113.32K | 515.91K | -3.03K | -7.58K | 2.09K | 17.05K | -578.10K | -1.77M | 0.00 | 0.00 |
| Net Income | -4.44M | -573.27K | -1.30M | -5.35M | -936.38K | -4.08M | -4.43M | -62.23K | -16.76K | -40.04K | -5.36K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 11,438.57% | 0.00% |
| EPS | -0.01 | -0.01 | -0.02 | -0.08 | -0.01 | -0.06 | -0.07 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.08 | -0.01 | -0.06 | -0.07 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 578.02M | 111.43M | 68.91M | 68.91M | 68.91M | 68.61M | 60.82M | 10.74M | 10.74M | 10.74M | 4.91M |
| Weighted Avg Shares Out (Dil) | 578.02M | 111.43M | 68.91M | 68.91M | 68.91M | 68.61M | 60.82M | 10.74M | 10.74M | 10.74M | 4.91M |
Source: https://incomestatements.info
Category: Stock Reports